Annual report pursuant to Section 13 and 15(d)

Acquisition of Pelican Therapeutics - Future Milestone Payments (Details)

v3.21.1
Acquisition of Pelican Therapeutics - Future Milestone Payments (Details) - University of Miami - USD ($)
$ in Millions
Jun. 22, 2020
Dec. 31, 2020
Payment under first milestone achieved $ 2.0  
Pelican Therapeutics, Inc.    
Future milestone payment upon Pelican's dosing of the first patient in its first Phase 2 trial for an oncology indication   $ 1.5
Future milestone payment upon successful outcome of the first Phase 2 trial for an oncology indication   3.0
Future milestone payment upon Pelican's dosing of the first patient in its first Phase 3 trial for an oncology indication   6.0
Future milestone payment upon Pelican's dosing of the first patient in its first Phase 3 trial for a non- oncology indication   3.0
Future milestone payment upon successful outcome of the first Phase 3 trial for an oncology indication   7.5
Future milestone payment upon successful outcome of the first Phase 3 trial for a non-oncology indication   3.0
Future milestone payment upon acceptance of a Biologics License Application (BLA) submission for an oncology indication   7.5
Future milestone payment upon acceptance of a BLA submission for a non-oncology indication   3.0
Future milestone payment upon first product indication approval in the United States or Europe for an oncology indication   7.5
Future milestone payment upon first product indication approval in the United States or Europe for a non- oncology indication   $ 3.0